[TimAlerts] RGLS making new highs in last hour

[TimAlerts] RGLS nhod

[TimAlerts] RGLS down 61%

[TimAlerts] RGLS Resumed down 52%

[TimAlerts] RGLS T1 Halt Clinical Hold. Conference call at 5:00pm EST

[TimAlerts] RGLS clinical hold. New lows likely on the way

[TimAlerts] RGLS T1 halt

[TimAlerts] RGLS spiking

[TimAlerts] RGLS Preliminary results release from RG-101 had it go from low 6s to mid 8s back in February

[TimAlerts] RGLS news - Regulus Therapeutics announces top-line results from the primary endpoint analysis of one of the company's ongoing phase II studies of RG-101 for the treatment of hepatitis C virus infection